Abstract
Purpose
Molecular basis of various forms of hyperinsulinemic hypoglycemia, involving defects in key genes regulating insulin secretion, are being increasingly reported. However, the management of medically unresponsive hyperinsulinism still remains a challenge as current facilities for genetic diagnosis and appropriate imaging are limited only to very few centers in the world. We aim to provide an overview of spectrum of clinical presentation, diagnosis and management of hyperinsulinism.
Methods
We searched the Cochrane library, MEDLINE and EMBASE databases, and reference lists of identified studies.
Conclusions
Analysis of blood samples, collected at the time of hypoglycemic episodes, for intermediary metabolites and hormones is critical for diagnosis and treatment. Increased awareness among clinicians about infants “at-risk” of hypoglycemia, and recent advances in genetic diagnosis have made remarkable contribution to the diagnosis and management of hyperinsulinism. Newer drugs like lanreotide (long acting somatostatin analogue) and sirolimus (mammalian target of rapamycin (mTOR) inhibitor) appears promising as patients with diffuse disease can be treated successfully without subtotal pancreatectomy, minimizing the long-term sequelae of diabetes and pancreatic insufficiency. Newer insights in understanding the molecular and histological basis and improvements in imaging and surgical techniques will modify the approach to patients with congenital hyperinsulinism.
Article PDF
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
References
Arya VB, Senniappan S, Guemes M, Hussain K. Neonatal hypoglycemia. Indian J Pediatr. 2014; 81:58–65.
Straussman S, Levitsky LL. Neonatal hypoglycemia. Curr Opin Endocrinol Diabetes Obes. 2010;17:20–4.
Menni F, de Lonlay P, Sevin C, Touati G, Peigne C, Barbier V, et al. Neurologic outcomes of 90 neonates and infants with persistent hyperinsulinemic hypoglycemia. Pediatrics. 2001;107:476–9.
Hussain K, Blankenstein O, De Lonlay P, Christesen HT. Hyperinsulinaemic hypoglycaemia: biochemical basis and the importance of maintaining normoglycaemia during management. Arch Dis Child. 2007;92:568–70.
Hawdon J. Glucose homeostasis in the healthy fetus and neonate. In: Rennie JM, editor. Metabolic and Endocrine Disorders. Textbook of Neonatology. London: Elsevier, Churchill Livingstone. 2005;851–52.
Henquin JC. Triggering and amplifying pathways of regulation of insulin secretion by glucose. Diabetes. 2000;49:1751–60.
Yorifuji T. Congenital hyperinsulinism: Current status and future prospectives. Ann Pediatr Endocrinol Metab. 2014;19:57–68.
Inagaki N, Gonoi T, Clement JP, Namba N, Inazawa J, Gonzalez G, et al. Reconstitution of IKATP: An inward rectifier subunit plus the sulfonylurea receptor. Science. 1995;270:1166–70.
Zhang T, Li C. Mechanisms of amino acid-stimulated insulin secretion in congenital hyperinsulinism. Acta Biochim Biophys Sin (Shanghai). 2013;45:36–43.
World Health Organization. Hypoglycaemia of the Newborn. Review of the Literature. Geneva: WHO, 1997;WHO/CHD/97.1.
Thornton PS, Stanley CA, De Leon D, Harris D, Haymond MW, Hussain K, et al. Recommendations from the Pediatric Endocrine Society for Evaluation and Management of Persistent Hypoglycemia in Neonates, Infants, and Children. J Pediatr. 2015; 167:238–45.
Tin W. Defining neonatal hypoglycaemia: a continuing debate. Semin Fetal Neonatal Med. 2014;19:27–32.
Adamkin DH, Committee on Fetus and Newborn. Postnatal glucose homeostasis in late-preterm and term infants. Pediatrics. 2011;127:575–79.
Kapoor RR, Flanagan SE, James C, Shield J, Ellard S, Hussain K. Hyperinsulinaemic hypoglycaemia. Arch Dis Child. 2009;94:450–7.
Vanhaltren K, Malhotra A. Characteristics of infants at risk of hypoglycaemia secondary to being ‘infant of a diabetic mother’. J Pediatr Endocrinol Metab. 2013;26:861–5.
Chong JH, Chandran S, Agarwal P, Rajadurai VS. Delayed presentation of prolonged hyperinsulinaemic hypoglycaemia in a preterm small-for-gestational age neonate. BMJ Case Rep. 2013. Doi:10.1136/bcr-2013-200920.
Bellanne-Chantelot C, Saint-Martin C, Ribeiro MJ, Vaury C, Verkarre V, Arnoux JB, et al. ABCC8 and KCNJ11 molecular spectrum of 109 patients with diazoxideunresponsive congenital hyperinsulinism. J Med Genet. 2010;47:752–59.
James C, Kapoor RR, Ismail D, Hussain K. The genetic basis of congenital hyperinsulinism. J Med Genet. 2009;46:289–99.
Mohammed Z, Hussain K. The genetics of hyperinsulinemic hypoglycemia. NeoReviews. 2013;14: 179–88.
Verkarre V, Fournet JC, de Lonlay P, Gross-Morand MS, Devillers M, Rahier J, et al. Paternal mutation of the sulfonylurea receptor (SUR1) gene and maternal loss of 11p15 imprinted genes lead to persistent hyperinsulinism in focal adenomatous hyperplasia. J Clin Invest. 1998;102:1286–91.
Flanagan SE, Clauin S, Bellanne-Chantelot C, de Lonlay P, Harries LW, Gloyn AL, et al. Update of mutations in the genes encoding the pancreatic b-cell K (ATP) channel subunits Kir6.2 (KCNJ11) and sulfonylurea receptor 1 (ABCC8) in diabetes mellitus and hyperinsulinism. Hum Mutat. 2009;30:170–80.
Stanley CA, Lieu YK, Hsu BY, Burlina AB, Greenberg CR, Hopwood NJ, et al. Hyperinsulinism and hyperammonemia in infants with regulatory mutations of the glutamate dehydrogenase gene. N Engl J Med. 1998;338:1352–7.
MacMullen C, Fang J, Hsu BY, Kelly A, de Lonlay-Debeney P, Saudubray JM, et al. Hyperinsulinism/hyperammonemia syndrome in children with regulatory mutations in the inhibitory guanosine triphosphate-binding domain of glutamate dehydrogenase. J Clin Endocrinol Metab. 2001;86:1782–7.
Hussain K, Clayton PT, Krywawych S, Chatziandreou I, Mills P, Ginbey DW, et al. Hyperinsulinism of infancy associated with a novel splice site mutation in the SCHAD gene. J Pediatr. 2005;146:706–8.
Chandran S, Yap F, Hussain K. Molecular mechanisms of protein induced hyperinsulinaemic hypoglycaemia. World J Diabetes. 2014;5:666–77.
Cuesta-Muñoz A, Huopio H, Otonkoski T, Gomez-Zumaquero JM, Näntö-Salonen K, Rahier J, et al. Severe persistent hyperinsulinemic hypoglycemia due to a de novo glucokinase mutation. Diabetes. 2004;53:2164–8.
Gonzalez Barroso MM, Giurgea I, Bouillaud F, Anedda A, Bellanne Chantelot C, Hubert L, et al. Mutations in UCP2 in congenital hyperinsulinism reveal a role for regulation of insulin secretion. PLoS One. 2008;3:e3850.
Gupta RK, Vatamaniuk MZ, Lee CS, Flaschen RC, Fulmer JT, Matschinsky FM, et al. The MODY1 gene HNF 4alpha regulates selected genes involved in insulin secretion. J Clin Invest. 2005;115:100615.
Pearson ER, Boj SF, Steele AM, Barrett T, Stals K, Shield JP, et al. Macrosomia and hyperinsulinaemic hypoglycaemia in patients with heterozygous mutations in the HNF4A gene. PLoS Med. 2007;4:e118.
Otonkoski T, Kaminen N, Ustinov J, Lapatto R, Meissner T, Mayatepek E, et al. Physical exercise-induced hyperinsulinemic hypoglycemia is an autosomal-dominant trait characterized by abnormal pyruvate induced insulin release. Diabetes. 2003;52:199–204.
Munns CF, Batch JA. Hyperinsulinism and Beckwith-Wiedemann syndrome. Arch Dis Child Fetal Neonatal Ed. 2001;84:F67–9.
Sun L, Eklund EA, Chung WK, Wang C, Cohen J, Freeze HH. Congenital disorder of glycosylation id presenting with hyperinsulinemic hypoglycemia and islet cell hyperplasia. J Clin Endocrinol Metab. 2005;90:4371–5.
Baumann U, Preece MA, Green A, Kelly DA, McKiernan PJ. Hyperinsulinism in tyrosinaemia type I. J Inherit Metab Dis. 2005;28:131–35.
Kapoor RR, Flanagan SE, Arya VB, Shield JP, Ellard S, Hussain K. Clinical and molecular characterisation of 300 patients with congenital hyperinsulinism. Eur J Endocrino. 2013;168:557–64.
Vannucci RC, Vannucci SJ. Hypoglycemic brain injury. Semin Neonatol. 2001;6:147–55.
Chandran S, Rajadurai VS, Alim AH, Hussain K. Current perspectives on neonatal hypoglycemia, its management, and cerebral injury risk. Research and Reports in Neonatology. 2015;5:17–30.
Mazor-Aronovitch K, Gillis D, Lobel D, Hirsch HJ, Pinhas-Hamiel O, Modan-Moses D, et al. Long-term neurodevelopmental outcome in conservatively treated congenital hyperinsulinism. Eur J Endocrinol. 2007;157:491–7.
Wang L, Fan G, Ji X, Sun B, Guo Q. MRI findings of brain damage due to neonatal hypoglycemia. Zhonghua Fang She Xue Za Zhi. 2009,43:42–5.
Deshpande S, Ward Platt M. The investigation and management of neo-natal hypoglycaemia. Semin Fetal Neonatal Med. 2005;10:351–61.
Senniappan S, Arya VB, Hussain K. The molecular mechanisms, diagnosis and management of congenital hyperinsulinism. Indian J Endocr Metab. 2013;17:19–30.
Harris DL, Battin MR, Weston PJ, Harding JE. Continuous glucose monitoring in newborn babies at risk of hypoglycemia. J Pediatr. 2010;157:198–202.
Saif M, Kapoor A, Kochar IP, Jindal R. Continuous glucose monitoring system for congenital hyperinsulinemia. Indian Pediatr. 2013;50:421–2.
Hussain K. Investigations for neonatal hypoglycaemia. Clin Biochem. 2011;44:465–6.
Hussain K, Blankenstein O, De Lonlay P, Christesen HT. Hyperinsulinaemic hypoglycaemia: biochemical basis and the impor-tance of maintaining normoglycaemia during management. Arch Dis Child. 2007;92:568–70.
Aynsley-Green A, Hussain K, Hall J, Saudubray JM, Nihoul-Fékété C, De Lonlay-Debeney P, et al. Practical management of hyperinsulinism in infancy. Arch Dis Child Fetal Neonatal Ed. 2000;82:F98–107.
Tas E, Mahmood B, Garibaldi L, Sperling M. Liver injury may increase the risk of diazoxide toxicity: a case report. Eur j Pediatr. 2015;174:403–6.
Hussain K. Diagnosis and management of hyperinsulinaemic hypoglycaemia of infancy. Horm Res. 2008;69:2–13.
Kim-Hanh Le Quan Sang, Jean-Baptiste Arnoux, Asmaa Mamoune, Saint-Martin C, Bellanné-Chantelot C, Valayannopoulos C, et al. Successful treatment of congenital hyperinsulinism with long-acting release octreotide. Eur J Endocrino. 2012;166:333–9.
Modan-Moses D, Koren I, Mazor-Aronovitch K, Pinhas-Hamiel O, Landau H. Treatment of congenital hyperinsulinism with Lanreotide acetate (Somatuline Autogel). J Clin Endocrinol Metab. 2011; 96:2312–7.
Moens K, Berger V, Ahn JM, Van Schravendijk C, Hruby VJ, Pipeleers D, et al. Assessment of the role of interstitial glucagon in the acute glucose secretory responsiveness of in situ pancreatic beta-cells. Diabetes. 2002;51:669–75.
Senniappan S, Alexandrescu S, Tatevian N, Shah P, Arya V, Flanagan S, et al. Sirolimus therapy in infants with severe hyperinsulinemic hypoglycemia. N Engl J Med. 2014;370:1131–7.
Hussain K, Aynsley-Green A. Hyperinsulinaemic hypoglycaemia in preterm neonates. Arch Dis Child Fetal Neonatal Ed. 2004;89:F65–7.
Mohnike K, Blankenstein O, Christesen HT, de Lonlay J, Hussain K, Koopmans KP, et al. Proposal for a standardized protocol for 18-F DOPA-PET (PET/CT) in congenital hyperinsulinism. Horm Res. 2006;66:40–2.
Bax KN, van der Zee DC. The laparoscopic approach towards hyperinsulinism in children. Sem Ped Surg. 2007;16:245–51.
Leibowitz G, Glaser B, Higazi AA, Salameh M, Cerasi E, Landau H. Hyperinsulinemic hypoglycemia of infancy (nesidioblastosis) in clinical remission: High incidence of diabetes mellitus and persistent beta-cell dysfunction at long-term follow-up. J Clin Endocrinol Metab. 1995;80:386–92.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Vora, S., Chandran, S., Rajadurai, V.S. et al. Hyperinsulinemic hypoglycemia in infancy: Current concepts in diagnosis and management. Indian Pediatr 52, 1051–1059 (2015). https://doi.org/10.1007/s13312-015-0772-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13312-015-0772-1